Related Experiment Video

Updated: Jun 25, 2025

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk
05:15

Viral Transgene Expression in Rodent Hearts and the Assessment of Cardiac Arrhythmia Risk

Published on: July 27, 2022

1.6K

COVID-19 Vaccines in the Pediatric Population: A Focus on Cardiac Patients

Ghena Lababidi1, Hossam Lababidi1, Fadi Bitar2

  • 1Faculty of Medicine, American University of Beirut Medical Center, Beirut, Lebanon.

The Canadian Journal of Infectious Diseases & Medical Microbiology = Journal Canadien Des Maladies Infectieuses Et De La Microbiologie Medicale
|May 23, 2024
PubMed

Insights

This review examines COVID-19 vaccine immunology in children aged 0-18 years, focusing on safety, efficacy, and cardiovascular implications for pediatric vaccine approval. It assesses available vaccines for children, considering the pandemic's impact.

Area of Science:

  • Pediatric immunology and infectious diseases.
  • Vaccine development and regulatory science.

Background:

  • The COVID-19 pandemic necessitated rapid vaccine development, with initial approvals for adult populations.
  • The safety and efficacy of these vaccines in pediatric, neonatal, and adolescent cohorts require careful evaluation.
  • Children generally experience lower incidence and severity of COVID-19 compared to adults.

Purpose of the Study:

  • To review vaccine immunology in children aged 0-18 years.
  • To discuss the impact of the COVID-19 pandemic on children.
  • To outline considerations for pediatric vaccine approval, including efficacy, safety, and transmission reduction.

Main Methods:

  • Literature review of vaccine immunology in pediatric populations.
  • Analysis of available COVID-19 vaccines for pediatric cohorts.
  • Examination of efficacy, advantages, disadvantages, and cardiovascular implications.

Main Results:

  • Discussion of vaccine immunology specific to children (0-18 years).
  • Evaluation of approved and potential pediatric COVID-19 vaccines.
  • Assessment of cardiovascular implications related to pediatric COVID-19 vaccination.

Conclusions:

  • Pediatric COVID-19 vaccination requires a thorough assessment of safety, efficacy, and specific pediatric considerations.
  • Available vaccines and their profiles for children aged 0-18 years are presented.
  • Future perspectives on pediatric vaccination strategies and cardiovascular dynamics are discussed.

More Related Videos

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model04:55

Author Spotlight: Simulating Pediatric Cardiac Surgery Using a Neonatal Piglet Model

Published on: May 26, 2023

765
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

631

Related Concept Videos

Vaccinations01:51

Vaccinations

Overview
44.4K
Imaging Studies for Cardiovascular System III: X-Ray01:20

Imaging Studies for Cardiovascular System III: X-Ray

The most common cardiovascular diagnostic test is an X-ray. It produces images of the heart, blood vessels, and adjacent structures.
Definition and Purpose
An X-ray, or radiograph, is a non-invasive method that uses ionizing radiation to take images of internal structures. It is mainly used in cardiac imaging to examine the heart, lungs, and major blood vessels, aiming to identify abnormalities in the heart's size, shape, and position, such as heart failure, congenital defects, and vascular...
173
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send...
1.4K
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
570
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K